Summary: A 59-year-old woman who had dyspnea and neck swelling for 10 days was admitted to the hospital. Malignant peritoneal mesothelioma was diagnosed previously. According to the clinical findings, and laboratory and pathologic examination, the patient was found to have disseminated venous thrombosis and antiphospholipid syndrome, which is treatment-resistant autoimmune paraneoplastic syndrome.
Cancer is the second most common acquired cause of hypercoagulability, accounting for 10% to 20% of spontaneous deep venous thrombosis. Indeed, 15% of patients with cancer have clinical thromboses and approximately 50% have thromboses on autopsy (1) . Antiphospholipid antibodies (APA) represent a heterogonous group of immunoglobulins directed against plasma proteins with an affinity for anionic (phospholipid) surfaces. The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by recurrent thromboses with anticardiolipin antibody titers and/or a positive lupus anticoagulant (LAC) test. Proposed mechanisms include antibody-mediated interference with coagulation homeostasis, activation of platelets and endothelial cells, and a T-cell immune response to serum phospholipid-binding proteins. Their association with the occurrence of thrombosis (arterial and venous), recurrent pregnancy loss, or both, has long been recognized, and defines the APS. In addition to SLE and primary APS, APA have been reported in many other disorders and connective tissue diseases, malignancies, drug exposure, infection, and also in the absence of underlying disease (2-6). We report a case of venous thrombosis of upper extremities and superior vena cava occurring in a patient with malignant peritoneal mesothelioma.
CASE REPORT
A 59-year-old woman who had dyspnea and neck swelling for 10 days was admitted to the hospital in September 2003. She had been diagnosed as having epithelial type malignant peritoneal mesothelioma at another oncology center in December 2002 and treated with carboplatin and paclitaxel via peripheral vein for three cycles until April 2003 when the treatment was discon-tinued due to stable disease. According to the patient's medical history, central venous access was not performed and there was no abortion or smoking as possible factors. She was exposed to environmental tremolite asbestos for 30 years in the Central Anatolia region of Turkey. Physical examination revealed significant edema in the upper extremities and neck, distention in neck veins, abdominal swelling, and subcutaneous plaques on palpation. On chest radiography, the mediastinum was wider than normal. Thoracal spiral computed tomography (CT) showed thrombosis in the superior vena cava and multiple mediastinal lymph nodes 1.5 cm largest in dimension ( Fig. 1) . Abdominal CT revealed peritoneal thickening and ascites. The bilateral external jugular veins, bilateral axillary and subclavian veins, and left brachial vein were totally thrombosed in Doppler ultrasonography (USG). In addition to imaging of those thromboses, weak flow to the superior vena cava from collateral vessels was detected with venography ( Fig. 2) .
A previous peritoneal biopsy was reevaluated in our center and malignant mesothelioma was confirmed. Cytoplasmic diffuse staining with keratin, vimentin, and calretinin was obtained. Neck USG revealed left supraclavicular lymphadenopathy measuring 24 × 10 mm and pathologic examination of an excisional biopsy of this lymph node showed metastasis of malignat mesothelioma (Fig. 3) . Metastatic malignant mesothelioma was diagnosed based on these findings. Hemoglobin was 9.3 g/dL (for women, normal, 12-16 g/dL), platelet count was 249 × 10 3 /µL (normal, 130-400 × 10 3 /µL), and the erythrocyte sedimentation rate was 102 mm/h (normal, 1-10 mm/h). Renal function and liver function test results were within normal limits. Coagulation tests including activated partial thromboplastin time was 29 seconds (normal, 23-35 sec); prothrombin time, 11.5 seconds (normal, 10.5-13.2 sec); INR 0.95 (normal, 0.9-1.1), fibrinogen 844 mg/dL (normal, 146-380 mg/dL); antithrombin III, 103% (normal, 63%-122%); DDimer 3.12 ugFEU/n (normal, 0-0.6); lupus anticoagulant (detection), 65.1 seconds (normal, 31-44 sec); lupus anticoagulant (correction), 42.4 seconds (normal, 30-38 sec); lupus anticoagulant ratio 1.53 (normal, 0-1.1); protein C, 90% (normal, 70%-140%); protein S, 118% (normal, 65%-140%); activated protein C resistance 4.24 (normal, 2.0); anticardiolipin antibody IgG negative; and anticardiolipin antibody IgM, 20 IU/mL (normal, <10). Methylene tetrahydrofolate reductase C677T heterozygosity was detected and factor V G6191A (Leiden) and prothrombin G202101 mutation was not detected with polymerase chain reaction.Autoimmune profile covering hepatitis B surface antigen, antihepatitis C virus antibody, anti-HIV, anti-nuclear factor, and anti-ds DNA were negative.
We started antiedema treatment with dexamethasone 16 mg/total, loop diuretic, and lowmolecular-weight heparin (Deltaparin) 200U/ kg/day as anticoagulant treatment. Despite 2.5 months of anticoagulant therapy, vena cava superior syndrome did not improve. Initially 250,000 U/h for 1 hour, then 100,000 U/h total FIG. 1. A, B . Spiral CT scans obtained after contrast administration through the right brachial vein show collateral vessels. There is no enhancing filling defect within the superior vena cava representing large thrombus, and enhancement of the vessel wall is seen.
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2,500,000 U streptokinase was administered via peripheral vein on 60th day of hospital admission. Control venography showed no difference in collateral vessels, and the clinical condition of the patient did not improve after this intervention. The patient died due to hospital infection in the third month of hospital admission. Malignant mesothelioma with disseminated venous thrombosis and antiphospholipid syndrome, which is treatment-resistant autoimmune paraneoplastic syndrome, was presented as a case report.
DISCUSSION
Antiphospholipid syndrome can be primary or associated with autoimmune disorders. Recently, increases in APA titers have been observed in some neoplastic disorders and APS has also been considered as a paraneoplastic rheumatic disorder (7-9).Estimates of APA in malignant disease vary. These include carcinomas of lung, kidney, colon, prostate gland, liver, ovary, trachea, and even thymoma (10, 11) . Mesothelioma-associated antiphospholipid syndrome with skin lesions and neuropathy was reported once in the literature. In this patient, there were paraesthesiae of the feet and lower legs, cutaneous necrosis, and livedo reticularis with mid-dermis containing organized thrombus over his insteps and lower calves (12) .
In 1988, Jude and colleagues, among a series of patients with positive lupus anticoagulant, found 17 patients who had a history of neoplasia, including hematologic malignancies, and a variety of solid tumors including carcinoma of the breast, uterus, ovary, tongue, and lip (13) .
In 1997, Finazzi and colleagues evaluated 319 patients with APA (primary APS in 207, SLE 112) who were observed for 5 years. Malignant neoplastic disorders developed in five patients: one breast carcinoma and four with nonHodgkin lymphoma. Five of 18 patients who died during the follow-up period had hematologic malignancies (14) .
Hypercoagulability and thrombosis have been recognized in patients with malignancies. Hyper- 
FIG. 3.
A lymph node biopsy from supraclavicular region demonstrates adenoid and papillary structure. Hemotoxylin and eosin stain, ×100.
coagulation disorders in patients with malignancy, including APS, often are resistant to anticoagulation. However, these coagulopathies have been shown to resolve with successful treatment of the underlying malignancy and exacerbations of APS have been reported in some malignancies following chemotherapy and immunotherapy (7, (15) (16) (17) .
To the best of our knowledge, association of malignant peritoneal mesothelioma and venous thrombosis of upper extremities with APA and LAC positivity has not been reported previously. Anticardiolipin antibody IgM and lupus anticoagulant were positive; no other reason was detected to cause thrombophilia in this patient. Treatment of chemoresistant malignancies as malignant mesothelioma in this patient cannot control the disease and the underlying coagulation abnormalities, including APS, can be exacerbated, so in these patients life-threatening thromboembolic events resistant to therapy can develop.
Mesothelioma is among the causes of malignancy-associated APS. Cytotoxic therapies can increase the risk of thrombosis in these patients. We think that investigation of the frequency of APA and consideration of prophylactic treatment strategies against thrombosis in patients with malignant mesothelioma is appropriate.
